NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
XERAVA (eravacycline) by RAPHAS. Approved for complicated intra-abdominal infections, hospital acquired bacterial pneumonia. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XERAVA (eravacycline) is an intravenous tetracycline antibiotic approved in 2018 for serious gram-negative and multidrug-resistant bacterial infections. It is indicated for complicated intra-abdominal infections, hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and carbapenem-resistant pathogens including Acinetobacter baumannii. The drug binds to bacterial ribosomes to inhibit protein synthesis, making it effective against resistant organisms.
$0.788MPart D
Peak11.5 years to LOEXERAVA is in peak lifecycle with modest Part D uptake (882 claims, $788K spend in 2023), suggesting a specialized hospital-acquired infection niche with stable but limited commercial expansion potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Clinical Trials (3)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Started May 2025
35 enrolled
Complicated Intra-abdominal Infections (cIAI)
Eravacycline Combination Therapy for MRAB
Started Jan 2024
20 enrolled
Pulmonary InfectionPneumonia, BacterialAcinetobacter Baumannii
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
Started Nov 2012
20 enrolled
Normal Drug Tolerance
Worked on XERAVA at RAPHAS? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.